Skip to main content
. 2016 Oct 26;48(4):326–332. doi: 10.1007/s12029-016-9885-6

Table 2.

Base case for cost per QALYs gained

Gemcitabine plus cisplatin Gemcitabine only Incremental
Cost (yen) 15,446,575 12,328,228 3,118,347
Eff. (QALMs) 10.04 7.61 2.73

Incremental cost-effectiveness ratio (ICER) = 3 yen, 118,347/2.73 QALMs = 13,707,020 yen/QALY gained >6,000,000/QALYs gained (not cost-effective)

QALY (M) quality-adjusted life year (month)